Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors that heterodimerize with RXR and bind PPRE (peroxisome proliferator response elements) to drive lipid + glucose metabolic gene expression. Three isoforms with distinct tissue distribution and pharmacology: PPARα (liver, BAT, muscle, kidney) — fatty acid β-oxidation, ketogenesis, lipoprotein metabolism (apoA-I/A-II, LPL); fibrates (fenofibrate, gemfibrozil) are PPARα agonists → ↑HDL, ↓TG. PPARγ (adipose, macrophage, colon) — adipogenesis, insulin sensitization, anti-inflammatory; thiazolidinediones (pioglitazone, rosiglitazone) are PPARγ agonists → insulin sensitization in T2D, but ↑edema/HF/bone-fracture risk. PPARδ/β (ubiquitous) — fatty acid oxidation in muscle, exercise mimetic; agonists (cardarine/GW501516 — banned in sport) and now seladelpar in PBC. Endogenous ligands: PUFAs (DHA, EPA, ALA — partial PPARα/γ agonists), oxidized lipids (15d-PGJ2 → PPARγ), nitro-fatty acids. Coactivator recruitment: PGC-1α (mitochondrial biogenesis), p300, SRC-1. Cross-talk: anti-inflammatory via NF-κB transrepression (PPARγ — pioglitazone benefit in atherosclerosis); ARB telmisartan is a partial PPARγ agonist (likely explains favorable metabolic profile). Cross-links: beta oxidation (PPARα target genes), insulin glucose homeostasis (PPARγ adipocyte action), fatty acid biosynthesis.
Organ Systems
cardiovascular
digestive
endocrine
musculoskeletal
Pathway Steps
free PUFA / eicosanoid / nitro-fatty acid → PPAR ligand-binding domain — via physiological ligand binding (PPARα: long-chain FAs; PPARγ: 15d-PGJ2 + oxidized LDL). The PPARs are lipid-sensing nuclear receptors: their large hydrophobic pockets are activated by free polyunsaturated fatty acids, eicosanoids, and nitro-fatty acids — making them direct transcriptional sensors of the cell’s lipid milieu. This endogenous-lipid logic is why dietary and metabolic fatty acids tune their target genes.
PPAR-ligand → PPAR-RXR heterodimer on PPRE — via corepressor (NCoR/SMRT) dissociation + coactivator (PGC-1α, p300, SRC-1) recruitment. Like other type-II nuclear receptors, a ligand-bound PPAR acts as an obligate heterodimer with RXR, binding PPAR response elements (PPREs). Ligand swaps corepressors for coactivators; because RXR is the shared partner, PPAR signaling intersects with retinoid and other RXR-partnered pathways.
PPARα-RXR on PPRE → CPT1A / ACOX1 / FABP1 transcription — via ↑fatty acid β-oxidation + ketogenesis (liver, muscle). PPARα (liver-enriched) drives fatty-acid catabolism — CPT1A for mitochondrial uptake, ACOX1 for peroxisomal β-oxidation, FABP1 for intracellular transport — the program switched on during fasting. It is the molecular target of the fibrate drugs used to lower triglycerides.
PPARα-RXR on PPRE → apoA-I / apoA-II / LPL transcription — via ↑HDL + ↓triglycerides (fibrate hypolipidemic mechanism). PPARα also reshapes plasma lipoproteins, inducing apoA-I/apoA-II (raising HDL) and lipoprotein lipase (LPL) while repressing apoC-III to speed triglyceride clearance. These transcriptional effects explain the lipid-profile changes produced by fibrates.
PPARγ-RXR on PPRE → aP2 / adiponectin / GLUT4 transcription — via adipogenesis + insulin sensitization (TZD mechanism). PPARγ is the master regulator of adipogenesis and insulin sensitivity, inducing aP2, adiponectin, and GLUT4 to promote fat storage and glucose uptake. It is the direct receptor for the thiazolidinedione (glitazone) insulin sensitizers — whose side effects (weight gain, fluid retention) also trace to PPARγ.
PPARγ + p65 NF-κB → transrepression of NF-κB targets — via anti-inflammatory mechanism — independent of PPRE binding. Beyond gene activation, ligand-bound PPARγ transrepresses inflammation: it is SUMOylated and tethered to NF-κB (p65) target promoters, keeping corepressor complexes in place. This ligand-dependent transrepression underlies the anti-inflammatory action of PPARγ agonists, independent of PPRE binding.
PPARδ-RXR on PPRE → muscle FA oxidation genes + slow-twitch fiber programme — via exercise-mimetic phenotype. PPARδ (ubiquitous) drives fatty-acid oxidation genes and the oxidative, slow-twitch muscle-fiber program — in effect an “exercise-mimetic” transcriptional output. Its agonists boost endurance and lipid handling in models, which is also why they have been abused as doping agents.